Junhemeng Biopharmaceutical

About Junhemeng Biopharmaceutical

Established in November 2020 and headquartered in Hangzhou, China, Junhemeng Biopharmaceutical (JHM) is a biopharmaceutical company specializing in the development and commercialization of synthetic biology products and recombinant protein drugs. The company's founding team possesses over two decades of experience in protein drug research and industrialization.

JHM's business model is centered on addressing needs in both consumer healthcare and therapeutic solutions. The company engages in the entire drug development lifecycle, from initial discovery and process development to clinical trials and manufacturing for product launch. Its core activities are focused on creating treatments for endocrine therapy, neurotherapy, anti-aging skincare, and developing next-generation biomedical materials. To support its operations, the company operates two GMP factories located in Hangzhou and Tonghua.

The company's product pipeline is concentrated on recombinant protein drugs with significant market potential. Key products in development include Recombinant Type I & III Human Collagen, Recombinant Type A Botulinum Toxin, Recombinant Human Growth Hormone, and a long-acting version of the growth hormone. JHM has developed a proprietary technology platform that features a high-yield expression system for recombinant proteins, mild denaturation purification technology, and systems for extracellular protein folding.

Financially, Junhemeng Biopharmaceutical has secured significant funding to advance its research and development. The company completed Series A and A+ financing, raising hundreds of millions of yuan to support clinical trials for its growth hormone products. A Series B round in May 2024 brought in an additional $13.8 million from investor Tonghua Dongbao Pharma. Other investors include Guofang Innovation, Hongsheng Capital, Oriza Holdings, SDIC Unity Capital, SoYoung, Guangdian Capital, and 3E Bioventures Capital.